scholarly journals Effect of Bacillus coagulans Unique IS-2 in Inflammatory Bowel Disease (IBD): A Randomized Controlled Trial

2021 ◽  
Author(s):  
Dr. V Deepak Bamola ◽  
Divya Dubey ◽  
Projoyita Samanta ◽  
Saurabh Kedia ◽  
Ratna Sudha Madempudi ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Treatment Group ◽  
Bowel Disease ◽  
Bacillus Coagulans ◽  
Treated Group ◽  
Good Survival ◽  
Therapeutic Effects ◽  
Post Intervention ◽  
Inflammatory Bowel ◽  
Serum Serotonin

Probiotic intervention is an important approach for the treatment and health restoration in inflammatory bowel disease (IBD). The preventive and therapeutic effects of probiotic Bacillus coagulans Unique IS-2 in different diseases have been well recognized but its efficacy in IBD is unreported. Therefore, a study was conducted to assess the effect of Bacillus coagulans Unique IS-2 in IBD patients. Subjects those satisfying compliance criteria were recruited in the study and given either probiotic B. coagulans Unique IS-2 or placebo for 4 weeks as per randomization. Survival of the given probiotic strain in GI, presence of beneficial gut bacteria, serum cytokines, serum serotonin and serum dopamine, symptoms of disease, physical, behavioral and psychological parameters of the subjects were evaluated before and after intervention. In this study B. coagulans Unique IS-2 was well tolerated with no severe adverse events in IBD patients. B coagulans Unique IS-2 demonstrated good survival in GI tract by significantly high detection in probiotic treated group (p <0.001). Significant enhancement in beneficial Lactobacilli was observed in probiotic treated group (p <0.01). NGS data and metagenomic analysis also showed an increase in the abundance of bacterial genera Bacillus, Lactobacillus, Bifidobacterium, Faecalibacterium, Bacteroides, Megamonas, Lachnospira, Blautia and Alistipes in the post intervention samples in the treatment group. A decrease in in the abundance of bacterial genera Sutterella, Dialister, Roseburia and Megasphaera was observed in post intervention samples in the treatment group. Increased secretion of cytokine IL-10 and variable decrease in the secretion of IL-6, IL-1β, TNF- α, IL -17 and IL -23 was observed in in the probiotic treated group. Post intervention change in serum serotonin and serum dopamine was not significant in both the groups. A reduction in the severity of disease symptoms and improvement in the physical, behavioral and psychological parameter was observed in the probiotic treated group. The observed results demonstrated that B. coagulans Unique IS-2 with SMT was effective in adult IBD patients. Study was registered with Clinical Trials Registry India (CTRI) - (registration reference- REF/2016/09/012181, CTRI registration No.- CTRI/2019/11/022087).

The Effect of Dietary Glutathione and Coenzyme Q10 on the Prevention and Treatment of Inflammatory Bowel Disease in Mice

2004 ◽  
Vol 74 (1) ◽  
pp. 74-85 ◽  
Author(s):  
Liu ◽  
Russell ◽  
Smith ◽  
Bronson ◽  
Milbury ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Dextran Sulfate ◽  
Coenzyme Q ◽  
Histological Evaluation ◽  
Therapeutic Effects ◽  
Prevention Study ◽  
Prevention And Treatment ◽  
Inflammatory Bowel ◽  
Pre Treatment

Because reactive oxygen species have been implicated as mediators of inflammatory bowel disease (IBD), we evaluated the potential preventive and therapeutic effects of two dietary antioxidants, glutathione (GSH) and coenzyme Q10 (CoQ10) on dextran sulfate sodium (DSS)-induced colitis in mice. Fifty female 8-wk old Swiss-Webster mice were randomly assigned to 4 groups for a pre-treatment 'prevention' study: (1) GSH (1% of diet); (2) CoQ10 (200 mg/kg/d); (3) DSS only (3% of drinking water); (4) control (no treatment). The mice in groups 1 and 2 were fed with GSH or CoQ10 for 21 wks, and the mice in groups 1, 2 and 3 were provided DSS from wk 7 for 4 cycles (1 cycle = 1 wk DSS followed by 2-wk water). Another 50 mice were randomly assigned to 4 groups for a 21-wk 'treatment' study where the mice in groups 1, 2, and 3 were administered DSS for 6 cycles (18 wks) to induce colitis. GSH and CoQ10 were added from wk 7 until the completion of the protocol. Loose stools and hemocult positivity were modestly but significantly reduced with GSH or CoQ10 at several periods during the intervention in both the prevention and treatment studies. In contrast, histological evaluation revealed increases in colonic dysplasia and ulceration with GSH or CoQ10. Thus, in this mouse model, GSH and CoQ10 appear to have a beneficial effect on acute signs of IBD, but may have an adverse impact on the chronic pathophysiology of the disease. Further studies using additional animal models are required to determine whether GSH or CoQ10 provide a favorable or unfavorable benefit:risk ratio in the prevention or treatment of IBD.

scholarly journals Therapeutic Effects of Beclomethasone Dipropionate Enemas on Colon Damage of Inflammatory Bowel Disease Model Rats

1998 ◽  
Vol 118 (6) ◽  
pp. 216-225 ◽  
Author(s):  
Shuji SHIMADA ◽  
Takao AOYAMA ◽  
Fuminori SHIBUYA ◽  
Katsuyoshi NAKAJIMA ◽  
Hajime KOTAKI ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Beclomethasone Dipropionate ◽  
Disease Model ◽  
Therapeutic Effects ◽  
Inflammatory Bowel

scholarly journals Prenatal exposure of extra vitamin D from fortification and later risk of inflammatory bowel disease

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
K S Duus ◽  
C M Moos ◽  
P Frederiksen ◽  
V Andersen ◽  
B L Heitmann
Keyword(s):  
Inflammatory Bowel Disease ◽  
Vitamin D ◽  
Prenatal Exposure ◽  
Bowel Disease ◽  
Therapeutic Effects ◽  
Birth Cohorts ◽  
Birth Registry ◽  
Fortified Food ◽  
Before And After ◽  
Inflammatory Bowel

Abstract Introduction Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammatory disease that can affect the entire digestive tract. Approximately 1% of the Danish population has IBD today. Both the incidence and prevalence of IBD are increasing globally, but the etiology of IBD is still not fully understood. Some, but not all studies find that vitamin D has both protective and therapeutic effects on IBD. To our knowledge, no other study has investigated prenatal exposure to extra vitamin D from either fortified food, diet or supplements in relation to IBD. The aim of this study was to investigate whether a small extra dose of vitamin D from fortification during gestation, was associated with a lower risk of developing IBD in the offspring. Methods In 1985 mandatory fortification of margarine with vitamin D in Denmark was canceled. To investigate the effect of this policy change we selected all individuals from 2 full year birth cohorts before and after the termination of the mandatory fortification. All individuals were followed for 30 years. By merging data from the Medical Birth Registry with the Danish National Patient Registry, we identified individuals with IBD. Results 217,249 individuals were included in the analysis. 875 among the exposed and 1102 among the unexposed fulfilled the criteria for being diagnosed with IBD. A lower odds ratio OR = 0.867 (95% CI: 0.792;0.947) for IBD was observed among those who had been exposed to extra vitamin D from fortified margarine during gestation, compared to those who had not been exposed. The analysis was adjusted for sex and season of birth, but results were essentially similar before and after this adjustment. Conclusions This study shows, that a small extra dose of vitamin D from fortified margarine during gestation may lower the risk of developing IBD in the offspring, until the age of 30. If these results can be replicated, fortification with vitamin D could be recommended to prevent IBD on a public level. Key messages Prenatal exposure of vitamin D from fortified food could lower the risk of IBD later in life. Fortification with vitamin D even at a relatively low level could have public health benefits.

scholarly journals Population Management: A Tool to Improve Timely Care in Pediatric and Young Adult Patients with Inflammatory Bowel Disease

2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Erealda Prendaj ◽  
Sharon Thomas ◽  
Gitit Tomer
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Population Management ◽  
Post Intervention ◽  
Median Percentage ◽  
Pareto Chart ◽  
Patient Nonadherence ◽  
Inflammatory Bowel ◽  
One Year

Background. Maintenance of health leads to better outcomes in patients with chronic illness. ImproveCareNow, an international inflammatory bowel disease (IBD) quality improvement (QI) network, recommends maintenance-of-health visits twice a year. We identified a gap in care, with only 64% of IBD patients having documented visits within 200 days. Therefore, we sought to improve our follow-up rate to a goal of 80%. Methods. Using population management (PM) reports, we identified patient-, data-, and treatment-related reasons for no documented visit within 200 days. We used the Pareto chart, key drivers, and process flow mapping and implemented changes using Plan-Do-Study-Act (PDSA) cycles to improve follow-up visit rates. Outcomes were presented using a control run chart with pre- and post- intervention data. Results. The most common reasons for no visits were patient nonadherence with appointments (50%) and relocation/transition to an adult provider (25%). The median percentage of documented visits within 200 days increased from 64% to 83% (p<0.0001), and this increase has been sustained for one year. Conclusions. Using the PM tool and focused QI interventions improved data quality and the percentage of patients with a documented visit within 200 days. The process is simple and can be applied to patients with other chronic illnesses.

scholarly journals Mechanism and therapeutic effect of umbilical cord mesenchymal stem cells in inflammatory bowel disease

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Xing-hua Pan ◽  
Qing-qing Li ◽  
Xiang-qing Zhu ◽  
Zi-an Li ◽  
Xue-min Cai ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Normal Control ◽  
Bowel Disease ◽  
Therapeutic Effects ◽  
Colon Tissue ◽  
Junction Protein ◽  
Inflammatory Bowel

AbstractInflammatory bowel disease (IBD) is a persistent and chronic disease that is characterized by destructive gastrointestinal (GI) inflammation. Researchers are trying to identify and develop new and more effective treatments with no side effects. Acute and chronic mouse models of IBD were established using dextran sulfate sodium (DSS) solution. To evaluate the efficacy and mechanism, umbilical cord mesenchymal stem cells (UCMSCs) were obtained from Kunming (KM) mice and humans. In the chronic IBD study, the survival rates of the normal control, model, mouse UCMSC (mUCMSC) and human UCMSC (hUCMSC) groups were 100%, 40%, 86.7%, and 100%, respectively. The histopathological scores of the normal control, intraperitoneal injection, intravenous treatment, and model groups were 0.5 ± 0.30, 5.9 ± 1.10, 8.7 ± 1.39, and 8.8 ± 1.33 (p = 0.021). UCMSCs promoted the expression of the intestinal tight junction protein occludin, downregulated the protein expression of the autophagy marker LC3A/B in colon tissue, and upregulated the expression of VEGF-A and VEGFR-1 at the injured site. This study provides an experimental model for elucidating the therapeutic effects of UCMSCs in IBD. We provide a theoretical basis and method for the clinical treatment of IBD using UCMSCs.

scholarly journals The Use of Virtual Reality to Reduce Stress among Inflammatory Bowel Disease Patients Treated with Vedolizumab

2021 ◽  
Vol 10 (12) ◽  
pp. 2709
Author(s):  
Konrad Lewandowski ◽  
Magdalena Kaniewska ◽  
Mariusz Rosołowski ◽  
Piotr Kucha ◽  
Grażyna Rydzewska
Keyword(s):  
Inflammatory Bowel Disease ◽  
Virtual Reality ◽  
Bowel Disease ◽  
Intervention Group ◽  
Well Being ◽  
Treated Group ◽  
Patient Comfort ◽  
Secondary Outcome ◽  
Medical Procedure ◽  
Inflammatory Bowel

(1) Background: The use of virtual reality (VR) in improving patient comfort related to medical procedures in oncology patients raised the question of whether similar benefits could be obtained by patients with inflammatory bowel disease (IBD). (2) Methods: In this prospective, randomized, controlled, single-center clinical trial, a total of 90 patients with IBD treated with vedolizumab were enrolled and randomized in a 1:1 allocation to either the VR immersion group or the routine-treated group. The primary outcome was to evaluate whether VR could decrease stress and anxiety related to a medical procedure. The secondary outcome was to assess the safety of the VR. (3) Results: A statistically significant improvement in well-being and psychological comfort (p = 0.046), feeling of relaxation (p = 0.046), sense of influence on the treatment process (p < 0.001), improved perception of the way the drug works (p < 0.001), improved positive attitude while waiting for the next administration of the drug (p = 0.026), and increased motivation for treatment (p = 0.026) was noticed in the intervention group. There were no statistically significant differences in the incidence of complications in the intervention and control groups. (4) Conclusions: The use of VR had a positive effect on the reduction of stress associated with vedolizumab treatment and could improve compliance.

Sign in / Sign up

Export Citation Format

Share Document